EPISODE · Sep 8, 2025 · 33 MIN
Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516
from Executive Insights for Life Sciences Innovators · host GeneCoda® Executive Search
In this episode of Executive Insights for Life Sciences Innovators, we speak with Anna Kazanchyan, MD, CEO of Saghmos Therapeutics, about the company’s mission to revolutionize cardiovascular and kidney protection. We explore how their lead drug candidate, ST-62516, is designed to prevent Major Adverse Cardiac and Kidney Events (MACKE) in high-risk patients undergoing PCI. Dr. Kazanchyan discusses the science behind ST-62516, why it has a strong likelihood of FDA approval, and the company’s strategic approach to clinical trials, regulatory success, and market exclusivity.Learn more at genecoda.com.Originally recorded and streamed on YouTube Live on March 28, 2025.
What this episode covers
In this episode of Executive Insights for Life Sciences Innovators, we speak with Anna Kazanchyan, MD, CEO of Saghmos Therapeutics, about the company’s mission to revolutionize cardiovascular and kidney protection. We explore how their lead drug candidate, ST-62516, is designed to prevent Major Adverse Cardiac and Kidney Events (MACKE) in high-risk patients undergoing PCI. Dr. Kazanchyan discusses the science behind ST-62516, why it has a strong likelihood of FDA approval, and the company’s strategic approach to clinical trials, regulatory success, and market exclusivity.Learn more at genecoda.com.Originally recorded and streamed on YouTube Live on March 28, 2025.
NOW PLAYING
Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m